The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization Therapy

Detalhes bibliográficos
Autor(a) principal: Serôdio, JF
Data de Publicação: 2016
Outros Autores: Oliveira, MM, Laranjo, S, Tavares, C, Cunha, PS, Abreu, A, Branco, LM, Alves, S, Rocha, I, Cruz Ferreira, R
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/3009
Resumo: INTRODUCTION: Baroreflex function is an independent marker of prognosis in heart failure (HF). However, little is known about its relation to response to cardiac resynchronization therapy (CRT). The aim of this study is to assess arterial baroreflex function in HF patients who are candidates for CRT. METHODS: The study population consisted of 25 patients with indication for CRT, aged 65±10 years, NYHA functional class ≥III in 52%, QRS width 159±15 ms, left ventricular ejection fraction (LVEF) 29±5%, left ventricular end-systolic volume (LVESV) 150±48 ml, B-type natriuretic peptide (BNP) 357±270 pg/ml, and peak oxygen consumption (peak VO2) 18.4±5.0 ml/kg/min. An orthostatic tilt test was performed to assess the baroreflex effectiveness index (BEI) by the sequence method. This group was compared with 15 age-matched healthy individuals. RESULTS: HF patients showed a significantly depressed BEI during tilt (31±12% vs. 49±18%, p=0.001). A lower BEI was associated with higher BNP (p=0.038), lower peak VO2 (p=0.048), and higher LVESV (p=0.031). By applying a cut-off value of 25% for BEI, two clusters of patients were identified: lower risk cluster (BEI >25%) QRS 153 ms, LVESV 129 ml, BNP 146 pg/ml, peak VO2 19.0 ml/kg/min; and higher risk cluster (IEB ≤25%) QRS 167 ms, LVESV 189 ml, BNP 590 pg/ml, peak VO2 16.2 ml/kg/min. CONCLUSIONS: Candidates for CRT show depressed arterial baroreflex function. Lower BEI was observed in high-risk HF patients. Baroreflex function correlated closely with other clinical HF parameters. Therefore, BEI may improve risk stratification in HF patients undergoing CRT.
id RCAP_e82f1669b08ad7d33901f1342db743cd
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/3009
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization TherapyO Índice de Eficácia do Barorreflexo na Estratificação de Risco de Doentes com Insuficiência Cardíaca Crónica Candidatos à Terapêutica de Ressincronização CardíacaAgedFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainRisk AssessmentStroke VolumeTreatment OutcomeBaroreflexCardiac Resynchronization TherapyHSM CARINTRODUCTION: Baroreflex function is an independent marker of prognosis in heart failure (HF). However, little is known about its relation to response to cardiac resynchronization therapy (CRT). The aim of this study is to assess arterial baroreflex function in HF patients who are candidates for CRT. METHODS: The study population consisted of 25 patients with indication for CRT, aged 65±10 years, NYHA functional class ≥III in 52%, QRS width 159±15 ms, left ventricular ejection fraction (LVEF) 29±5%, left ventricular end-systolic volume (LVESV) 150±48 ml, B-type natriuretic peptide (BNP) 357±270 pg/ml, and peak oxygen consumption (peak VO2) 18.4±5.0 ml/kg/min. An orthostatic tilt test was performed to assess the baroreflex effectiveness index (BEI) by the sequence method. This group was compared with 15 age-matched healthy individuals. RESULTS: HF patients showed a significantly depressed BEI during tilt (31±12% vs. 49±18%, p=0.001). A lower BEI was associated with higher BNP (p=0.038), lower peak VO2 (p=0.048), and higher LVESV (p=0.031). By applying a cut-off value of 25% for BEI, two clusters of patients were identified: lower risk cluster (BEI >25%) QRS 153 ms, LVESV 129 ml, BNP 146 pg/ml, peak VO2 19.0 ml/kg/min; and higher risk cluster (IEB ≤25%) QRS 167 ms, LVESV 189 ml, BNP 590 pg/ml, peak VO2 16.2 ml/kg/min. CONCLUSIONS: Candidates for CRT show depressed arterial baroreflex function. Lower BEI was observed in high-risk HF patients. Baroreflex function correlated closely with other clinical HF parameters. Therefore, BEI may improve risk stratification in HF patients undergoing CRT.Elsevier EspañaRepositório do Centro Hospitalar Universitário de Lisboa Central, EPESerôdio, JFOliveira, MMLaranjo, STavares, CCunha, PSAbreu, ABranco, LMAlves, SRocha, ICruz Ferreira, R2018-08-06T14:43:32Z2016-062016-06-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/3009engRev Port Cardiol. 2016 Jun;35(6):343-50.10.1016/j.repc.2015.11.021info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:40:47Zoai:repositorio.chlc.min-saude.pt:10400.17/3009Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:20:19.239568Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization Therapy
O Índice de Eficácia do Barorreflexo na Estratificação de Risco de Doentes com Insuficiência Cardíaca Crónica Candidatos à Terapêutica de Ressincronização Cardíaca
title The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization Therapy
spellingShingle The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization Therapy
Serôdio, JF
Aged
Female
Heart Failure
Humans
Male
Middle Aged
Natriuretic Peptide, Brain
Risk Assessment
Stroke Volume
Treatment Outcome
Baroreflex
Cardiac Resynchronization Therapy
HSM CAR
title_short The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization Therapy
title_full The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization Therapy
title_fullStr The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization Therapy
title_full_unstemmed The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization Therapy
title_sort The Arterial Baroreflex Effectiveness Index in Risk Stratification of Chronic Heart Failure Patients Who Are Candidates for Cardiac Resynchronization Therapy
author Serôdio, JF
author_facet Serôdio, JF
Oliveira, MM
Laranjo, S
Tavares, C
Cunha, PS
Abreu, A
Branco, LM
Alves, S
Rocha, I
Cruz Ferreira, R
author_role author
author2 Oliveira, MM
Laranjo, S
Tavares, C
Cunha, PS
Abreu, A
Branco, LM
Alves, S
Rocha, I
Cruz Ferreira, R
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Serôdio, JF
Oliveira, MM
Laranjo, S
Tavares, C
Cunha, PS
Abreu, A
Branco, LM
Alves, S
Rocha, I
Cruz Ferreira, R
dc.subject.por.fl_str_mv Aged
Female
Heart Failure
Humans
Male
Middle Aged
Natriuretic Peptide, Brain
Risk Assessment
Stroke Volume
Treatment Outcome
Baroreflex
Cardiac Resynchronization Therapy
HSM CAR
topic Aged
Female
Heart Failure
Humans
Male
Middle Aged
Natriuretic Peptide, Brain
Risk Assessment
Stroke Volume
Treatment Outcome
Baroreflex
Cardiac Resynchronization Therapy
HSM CAR
description INTRODUCTION: Baroreflex function is an independent marker of prognosis in heart failure (HF). However, little is known about its relation to response to cardiac resynchronization therapy (CRT). The aim of this study is to assess arterial baroreflex function in HF patients who are candidates for CRT. METHODS: The study population consisted of 25 patients with indication for CRT, aged 65±10 years, NYHA functional class ≥III in 52%, QRS width 159±15 ms, left ventricular ejection fraction (LVEF) 29±5%, left ventricular end-systolic volume (LVESV) 150±48 ml, B-type natriuretic peptide (BNP) 357±270 pg/ml, and peak oxygen consumption (peak VO2) 18.4±5.0 ml/kg/min. An orthostatic tilt test was performed to assess the baroreflex effectiveness index (BEI) by the sequence method. This group was compared with 15 age-matched healthy individuals. RESULTS: HF patients showed a significantly depressed BEI during tilt (31±12% vs. 49±18%, p=0.001). A lower BEI was associated with higher BNP (p=0.038), lower peak VO2 (p=0.048), and higher LVESV (p=0.031). By applying a cut-off value of 25% for BEI, two clusters of patients were identified: lower risk cluster (BEI >25%) QRS 153 ms, LVESV 129 ml, BNP 146 pg/ml, peak VO2 19.0 ml/kg/min; and higher risk cluster (IEB ≤25%) QRS 167 ms, LVESV 189 ml, BNP 590 pg/ml, peak VO2 16.2 ml/kg/min. CONCLUSIONS: Candidates for CRT show depressed arterial baroreflex function. Lower BEI was observed in high-risk HF patients. Baroreflex function correlated closely with other clinical HF parameters. Therefore, BEI may improve risk stratification in HF patients undergoing CRT.
publishDate 2016
dc.date.none.fl_str_mv 2016-06
2016-06-01T00:00:00Z
2018-08-06T14:43:32Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/3009
url http://hdl.handle.net/10400.17/3009
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Rev Port Cardiol. 2016 Jun;35(6):343-50.
10.1016/j.repc.2015.11.021
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier España
publisher.none.fl_str_mv Elsevier España
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131299724656640